Anatomical-Clinical Base of Adenocarcinoma Pancreatic (BACAP-2)

March 16, 2026 updated by: University Hospital, Toulouse
BACAP-2 is a prospective biobank dedicated to the pancreatic adenocarcinoma including clinical data and biological samples from tumor. The aim is to enrich the previous propective collection BACAP in order to support future research projects.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Pancreatic cancer represents the fourth cause of death by cancer in Western countries. In over 90% of cases, it is due to an adenocarcinoma. The only curative treatment for pancreatic cancer remains the surgical exeresis. This one can only be suggested as a curative treatment in only 10 to 15% of cases. Besides, prevention or screening is difficult to set up due to the absence of clearly identified risk factors or groups and to the absence of useful markers for the diagnosis in clinical practice.

The research efforts in this area must face a double challenge: saving time while improving the diagnosis period and strengthen the therapeutic equipment. It is important to identify and characterise the new molecular markers applicable for a better diagnosis and/or treatment (especially the response factors to chemotherapy).

The present project aims to enrich with fresh tumor tissue and somatic genetic analysis the existing propective collection BACAP in order to support support future research projects on:

  • the development of new diagnostic tools,
  • understanding the development of tumors of the pancreas
  • the development of new therapeutic targets
  • understanding the response to chemotherapy…

Study Type

Observational

Enrollment (Estimated)

1500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • France
      • Bordeaux, France, 33604
      • Béthune, France, 62408
      • Lille, France, 59037
        • Not yet recruiting
        • Huriez Hospital
        • Principal Investigator:
          • Guillaume PIESSEN, MD
        • Contact:
        • Principal Investigator:
          • Stépahnie TRUANT, MD
      • Lyon, France, 69008
        • Not yet recruiting
        • Jean Mermoz private hosptila
        • Contact:
        • Sub-Investigator:
          • Pascal ARTRU, MD
        • Sub-Investigator:
          • Bertrand PUJOL, MD
        • Sub-Investigator:
          • Fabien FUMEX, MD
        • Sub-Investigator:
          • Jérôme DESRAME, MD
        • Sub-Investigator:
          • Gérard LLEDO, MD
        • Sub-Investigator:
          • Christine LEFORT, MD
        • Sub-Investigator:
          • Vincent LEPILLIEZ, MD
      • Montpellier, France, 34295
      • Montpellier, France, 34298
      • Pau, France, 6400
      • Toulouse, France, 31059
        • Recruiting
        • Rangueil Hospital
        • Sub-Investigator:
          • Fabrice MUSCARI, MD
        • Sub-Investigator:
          • Nicolas CARRERE, MD
        • Contact:
        • Sub-Investigator:
          • Rosine GUIMBAUD, MD
        • Sub-Investigator:
          • Corinne COUTEAU, MD
        • Sub-Investigator:
          • Marion DESLANDRES, MD
        • Sub-Investigator:
          • Pascale RIVERA, MD
        • Sub-Investigator:
          • Marion JAFFRELOT, MD
        • Sub-Investigator:
          • Nadim FARES, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with a pancreatic adenocarcinoma proven cytologically or histologically without any treatment

Description

Inclusion Criteria:

  • Patient with pancreatic mass syndrome explored by ultrasound endoscopy with cytopuncture or
  • Patient with pancreatic mass syndrome explored by an abdominal scanner with and without injection of product contrast and/or puncture of the mass or secondary lesions by radiological route or
  • Patient with pancreatic adenocarcinoma proven histologically and/or cytologically

Exclusion Criteria:

  • Patient with a pancreatic tumor whose analysis histological is not an adenocarcinoma
  • Pregnant or breastfeeding patient

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Enrichment of prospective BACAP collection
Time Frame: 5 years
This collection is coming to enrich the prospective BACAP collection of fresh tumor tissue and/or fixed from the micro-biopsy under endoscopic ultrasound
5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Toulouse

Investigators

  • Principal Investigator: Barbara BOURNET, MD, PhD, University Hospital, Toulouse

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 16, 2023

Primary Completion (Estimated)

January 31, 2035

Study Completion (Estimated)

February 28, 2035

Study Registration Dates

First Submitted

November 7, 2023

First Submitted That Met QC Criteria

November 7, 2023

First Posted (Actual)

November 13, 2023

Study Record Updates

Last Update Posted (Actual)

March 19, 2026

Last Update Submitted That Met QC Criteria

March 16, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RC31/21/0191
  • 2021-A01050-41 (Other Identifier: ID-RCB)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Neoplasms

Clinical Trials on collection of biological samples

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe